Methods of using sustained release aminopyridine compositions
AssigneeAcorda Therapeutics, Inc.
InventorsAndrew R. Blight, Ron Cohen
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.
Claims17
A method of treating multiple sclerosis in a subject comprising administering a sustained release composition comprising 10 milligrams of 4-aminopyridine twice daily to said subject, wherein said multiple sclerosis is selected from relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis and progressive-relapsing multiple sclerosis.
A method of treating multiple sclerosis in a subject comprising
- administering to said subject an immunomodulator;
- and
- administering to said subject to said subject a sustained release composition comprising 10 milligrams of 4-aminopyridine twice daily.
A method of treating spasticity associated with multiple sclerosis in a subject comprising administering a sustained release composition comprising 10 milligrams of 4-aminopyridine twice daily to said subject, wherein the spasticity of said subject is decreased.
A method of treating multiple sclerosis in a subject comprising
- measuring said patient's creatinine clearance;
- and
- administering a sustained release composition comprising 10 milligrams of 4-aminopyridine twice daily to said subject if said subject's creatinine clearance is greater than or equal to 30 ml/min.
A method of treating multiple sclerosis multiple sclerosis in a subject comprising
- measuring said patient's creatinine clearance;
- and
- administering a sustained release composition comprising 4-aminopyridine, wherein the amount and the frequency of administration to said patient is dependent upon the measured creatinine clearance.
A method of testing the efficacy of a sustained release composition comprising 4-aminopyridine for treating multiple sclerosis comprising:
- assessing potential patients for study, based on particular inclusion and exclusion criteria, excluding patients with creatinine clearance rates below about 30 mL/min;
- assigning known portions of patients to placebo and Fampridine-SR groups, unknown to them or an evaluator in a double-blind study for receipt of placebo or Fampridine-SR;
- and
- assessing one or more of walking speed, leg strength, and spasticity over the course of 8 weeks of treatment.
A method assessing the efficacy of a sustained release composition comprising 4-aminopyridine for treating multiple sclerosis comprising
- assigning known portions of a sample of patients with multiple sclerosis to placebo and Fampridine-SR groups, unknown to them or an evaluator in a double-blind study for receipt of placebo or Fampridine-SR;
- and
- assessing one or more of walking speed, leg strength, and spasticity for said patients over the course of treatment;
- wherein the size of said sample of patients shall provide about 90% power and a statistical significance level of 0.05 or lower.
Dependencies are inferred from the claim text.